BioArctic (Sweden) Performance
| BIOA-B Stock | SEK 193.10 5.60 2.99% |
On a scale of 0 to 100, BioArctic holds a performance score of 5. The firm shows a Beta (market volatility) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioArctic's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioArctic is expected to be smaller as well. Please check BioArctic's standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether BioArctic's price patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in BioArctic AB are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, BioArctic sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 999.9 M | |
| Total Cashflows From Investing Activities | -4.4 M |
BioArctic |
BioArctic Relative Risk vs. Return Landscape
If you would invest 16,410 in BioArctic AB on September 1, 2024 and sell it today you would earn a total of 2,900 from holding BioArctic AB or generate 17.67% return on investment over 90 days. BioArctic AB is generating 0.3511% of daily returns and assumes 4.747% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than BioArctic, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioArctic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioArctic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioArctic AB, and traders can use it to determine the average amount a BioArctic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.074
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIOA-B | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.75 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.35 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average BioArctic is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioArctic by adding it to a well-diversified portfolio.
BioArctic Fundamentals Growth
BioArctic Stock prices reflect investors' perceptions of the future prospects and financial health of BioArctic, and BioArctic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioArctic Stock performance.
| Return On Equity | -0.0142 | |||
| Return On Asset | -0.0055 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 73.73 M | |||
| Price To Earning | 12.95 X | |||
| Price To Book | 32.29 X | |||
| Price To Sales | 111.27 X | |||
| Revenue | 23.15 M | |||
| EBITDA | (126.63 M) | |||
| Cash And Equivalents | 848.4 M | |||
| Cash Per Share | 13.84 X | |||
| Total Debt | 7.79 M | |||
| Debt To Equity | 3.00 % | |||
| Book Value Per Share | 8.92 X | |||
| Cash Flow From Operations | (140.46 M) | |||
| Earnings Per Share | 0.31 X | |||
| Total Asset | 897.73 M | |||
About BioArctic Performance
By analyzing BioArctic's fundamental ratios, stakeholders can gain valuable insights into BioArctic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioArctic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioArctic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioArctic AB , a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden. BioArctic is traded on Stockholm Stock Exchange in Sweden.Things to note about BioArctic AB performance evaluation
Checking the ongoing alerts about BioArctic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioArctic AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioArctic AB had very high historical volatility over the last 90 days | |
| The company reported the revenue of 23.15 M. Net Loss for the year was (119.79 M) with profit before overhead, payroll, taxes, and interest of 155.53 M. | |
| BioArctic AB has accumulated about 848.4 M in cash with (140.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.84. | |
| Roughly 48.0% of the company shares are held by company insiders |
- Analyzing BioArctic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioArctic's stock is overvalued or undervalued compared to its peers.
- Examining BioArctic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioArctic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioArctic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioArctic's stock. These opinions can provide insight into BioArctic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioArctic Stock analysis
When running BioArctic's price analysis, check to measure BioArctic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioArctic is operating at the current time. Most of BioArctic's value examination focuses on studying past and present price action to predict the probability of BioArctic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioArctic's price. Additionally, you may evaluate how the addition of BioArctic to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |